The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Novel strategies in colorectal cancer beyond targeting RAS and RAF
Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, provides an overview of emerging treatments in colorectal cancer, including antibody drug conjugates, bispecific antibodies, and CAR-Ts. Engineered CTLA-4 antibodies have showed efficacy in MSS tumors but the key challenge is how to integrate these new strategies into existing treatment protocols. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The new development in emergency treatments are antibody conjugates, bispecific antibodies, new engineered CTLA-4 antibodies, as well as CAR-Ts. CAR-Ts, ADCs, and bispecifics depend on really the target of cancer-specific expression of antigens. So they are overlapping, but the bispecifics usually have one target to really attract the immune cell trafficking into the tumor...
The new development in emergency treatments are antibody conjugates, bispecific antibodies, new engineered CTLA-4 antibodies, as well as CAR-Ts. CAR-Ts, ADCs, and bispecifics depend on really the target of cancer-specific expression of antigens. So they are overlapping, but the bispecifics usually have one target to really attract the immune cell trafficking into the tumor. So different approaches because the antibody conjugates will really do targeted delivery of cytotoxic, usually for colon cancer, a topo isomerase one. But novel engineered CTLA-4 antibodies show very good efficacy in MSS tumors, except the liver metastases. But this will certainly be paradigm changing as soon as the registration trials are completed. The CAR-Ts are extremely exciting because early data show response rates of 50% with novel, targeted, and engineered CAR-T cells. So the future is very exciting. The question is, how do we all integrate? And at what level of lines of treatment do we integrate the new treatment strategies?
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
